151,500 Shares in AtriCure, Inc. (NASDAQ:ATRC) Purchased by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 151,500 shares of the medical device company's stock, valued at approximately $4,630,000. Oberweis Asset Management Inc. owned approximately 0.31% of AtriCure at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new stake in AtriCure during the 4th quarter valued at about $9,168,000. Kennedy Capital Management LLC increased its position in shares of AtriCure by 29.8% during the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after acquiring an additional 172,648 shares in the last quarter. Marshall Wace LLP raised its holdings in AtriCure by 37.1% in the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock worth $18,922,000 after acquiring an additional 167,476 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in AtriCure by 24.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company's stock valued at $21,398,000 after purchasing an additional 136,015 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of AtriCure in the 4th quarter worth $3,716,000. 99.11% of the stock is owned by institutional investors.

Insider Buying and Selling

In other AtriCure news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now owns 17,828 shares of the company's stock, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

ATRC has been the topic of several recent analyst reports. Piper Sandler increased their price objective on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. JMP Securities reiterated a "market outperform" rating and issued a $60.00 price target on shares of AtriCure in a research note on Wednesday. Needham & Company LLC lowered their price objective on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Wednesday. UBS Group cut their target price on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Stifel Nicolaus increased their price target on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $50.67.

AtriCure Price Performance

Shares of AtriCure stock traded down $4.58 during trading hours on Wednesday, hitting $30.07. The company's stock had a trading volume of 1,236,937 shares, compared to its average volume of 660,348. The company has a market cap of $1.49 billion, a PE ratio of -31.65 and a beta of 1.65. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The business has a 50 day moving average price of $34.12 and a two-hundred day moving average price of $34.70. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The company had revenue of $123.62 million for the quarter, compared to analysts' expectations of $122.92 million. During the same period in the previous year, the firm earned ($0.28) EPS. The firm's revenue was up 13.5% compared to the same quarter last year. Analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.